New chemo cocktail aims to treat rare lymphoma without heart damage

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Understand and voluntarily sign the informed consent form 2. Age ≥ 65 years at enrollment 3. ECOG performance status score ≤ 2 4. Able to comply with the research visit plan and other protocol requirements 5. Patients with histologically confirmed peripheral T-cell lymphoma (PTCL) who have not previously received treatment The following subtypes as defined by the World Health Organization (WHO) classification (2022) are eligible, with Ann Arbor stage I-IV, and pathological immunohistochemical CD30 negative: 1. Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) 2. Nodal T-follicular helper cell lymphoma (TFH) 3. Anaplastic large cell lymphoma, ALK-negative (ALCL) 6. Life expectancy ≥ 3 months 7. Hematological, renal, and hepatic function all meet the requirements: 1. Absolute neutrophil count (ANC) ≥ 1,500/μL 2. Platelet count ≥ 100,000/μL 3. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) for the institution (except for patients with Gilbert's syndrome) 4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; if liver involvement is known, then ≤ 5.0 × ULN 5. Serum creatinine ≤ 1.5 × ULN, or creatinine clearance \> 50 mL/min calculated by the Cockcroft-Gault formula Exclusion Criteria: 1. Mental illness, disability, or social circumstances that may affect participant safety, ability to provide informed consent, or poor adherence 2. Other types of lymphoma 3. Previous immunotherapy or chemotherapy for PTCL, excluding those who used corticosteroids (≤8 days) prior to enrollment 4. Previous radiotherapy for PTCL, excluding those confined to a single lymph node region 5. Pathological immunohistochemistry showing CD30 positivity and/or ALK positivity 6. Patients planning to receive autologous or allogeneic transplantation as first-line consolidation therapy 7. Confirmed central nervous system/meningeal involvement 8. Significant uncontrolled comorbidities or infections, specifically: 1. Uncontrolled infection requiring intravenous antibiotics 2. Clinically significant heart disease (NYHA Class III or IV), unstable angina 3. History of angioplasty, stent implantation, or myocardial infarction within the past 6 months 4. Uncontrolled hypertension (systolic blood pressure \>160 mmHg) despite using two antihypertensive medications. (or diastolic blood pressure \>100 mmHg, measured twice consecutively, one week apart) 5. Clinically significant cardiac arrhythmias 6. Uncontrolled diabetes 9. Known or detected positive for human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV-1), hepatitis B, or hepatitis C. 10. Patients diagnosed with malignancy within the past two years. However, the following are excluded: non-melanoma skin cancer, melanoma in situ, localized prostate cancer (current PSA \<0.1 ng/mL), treated thyroid cancer; or cervical carcinoma in situ or breast ductal/lobular carcinoma in situ within the past two years, provided there is currently no evidence of active disease.